AI Analysis

Log in to generate an AI summary for this stock.

Log in to generate a MOAT report for this stock.

Log in to generate an earnings report for this stock.

Log in to generate an operating leverage report for this stock.

Log in to generate a management report for this stock.

Log in to generate a valuation report for this stock.

Sana Biotechnology, Inc.

$3.13 -$1.06 (-25.30%)
NASDAQ · 11 Sep 2026 20:00 UTC
Previous Close
$3.09
Day Range
$3.01$3.17
Year Range
$2.61$6.55
Market Cap
871.05M
AVG Volume
3.42M
Trailing/Forward PE
-4.12/-
PEG ratio
0.3
Dividend Yield
-
Next Earnings Date
2026-11-05
Primary Exchange
NASDAQUS
Net Income (USD)
-400M-300M-200M-100M0202020212022202320242025
SANA Net Income (USD) by year
PeriodNet Income (USD)
2025-244.17M
2024-266.76M
2023-283.25M
2022-269.48M
2021-355.93M
2020-285.31M
Operating Income (USD)
-400M-300M-200M-100M0202020212022202320242025
SANA Operating Income (USD) by year
PeriodOperating Income (USD)
2025-250.32M
2024-272.72M
2023-293.14M
2022-272.56M
2021-356.91M
2020-286.15M
EBITDA (USD)
-400M-300M-200M-100M0202020212022202320242025
SANA EBITDA (USD) by year
PeriodEBITDA (USD)
2025-187.98M
2024-249.37M
2023-258.7M
2022-253.85M
2021-333.6M
2020-280.23M
Cash Flows (USD)
-400M-300M-200M-100M0202020212022202320242025
SANA Cash Flows (USD) by year
PeriodCash Flows (USD)
2025-144.77M
2024-256.58M
2023-273.61M
2022-310.93M
2021-280.92M
2020-161.85M
EPS (USD)
-2-1.5-1-0.50202020212022202320242025
SANA EPS (USD) by year
PeriodEPS (USD)
2025-0.96
2024-1.16
2023-1.47
2022-1.43
2021-1.96
2020-1.96
Expenses (USD)
0100M200M300M400MR&DSG&ACapex202020212022202320242025
SANA Expenses (USD) by year
PeriodExpenses (USD)
2025206.65M
2024306.15M
2023313.17M
2022293.44M
2021386.77M
2020310.02M
Cash & Debt (USD)
0200M400M600M202020212022202320242025
SANA Cash & Debt (USD) by year
PeriodCash & Debt (USD)
2025138.38M
2024152.5M
2023205.19M
2022423.96M
2021551M
2020378.26M
Debt ratios
00.030.050.080.1202320242025
SANA Debt ratios by year
PeriodDebt ratios
20250.06
20240.05
20230.09
Return on Capital
-200%-100%0%100%202020212022202320242025
SANA Return on Capital by year
PeriodReturn on Capital
2025-151.77%
2024-106.49%
2023-98.52%
2022-53.97%
2021-48.86%
202067.74%
Shares Outstanding
0100M200M300M202020212022202320242025
SANA Shares Outstanding by year
PeriodShares Outstanding
2025253.23M
2024236.3M
2023197.32M
2022190.42M
2021183.99M
2020175.31M
Book Value Per Share (USD)
-4-2024202020212022202320242025
SANA Book Value Per Share (USD) by year
PeriodBook Value Per Share (USD)
20250.64
20241.06
20231.46
20222.62
20213.96
2020-2.4
Total Assets (USD)
0500M1B1.5B202020212022202320242025
SANA Total Assets (USD) by year
PeriodTotal Assets (USD)
2025416.89M
2024501.02M
2023565.3M
2022822.72M
20211.13B
2020730.3M
Employee Count
020040060020202021202220242025
SANA Employee Count by year
PeriodEmployee Count
2025142
2024194
2022421
2021383
2020265
Free Cash Flow Yield
-80%-60%-40%-20%0%med -19.99%Dec 24Apr 25Jul 25Oct 25Feb 26May 26Sep 26
SANA Free Cash Flow Yield by year
PeriodFree Cash Flow Yield
Sep 26-14.59%
Sep 26-11.87%
Aug 26-11.62%
Aug 26-11.68%
Aug 26-12.87%
Aug 26-13.71%
Jul 26-15.42%
Jul 26-15.18%
Jul 26-15.32%
Jul 26-12.54%
Jul 26-12.04%
Jun 26-14.11%
Jun 26-15.32%
Jun 26-18.01%
Jun 26-18.01%
May 26-14.63%
May 26-15.72%
May 26-15.72%
May 26-16.29%
May 26-17.48%
Apr 26-17.38%
Apr 26-16.24%
Apr 26-18.5%
Apr 26-17.86%
Mar 26-20.64%
Mar 26-18.38%
Mar 26-17.01%
Mar 26-18.15%
Feb 26-14.48%
Feb 26-15.21%
Feb 26-15.84%
Feb 26-15.52%
Jan 26-13.77%
Jan 26-12.63%
Jan 26-13.31%
Jan 26-13.37%
Jan 26-14.55%
Dec 25-13.83%
Dec 25-13.99%
Dec 25-11.86%
Dec 25-11.89%
Nov 25-14.18%
Nov 25-18.53%
Nov 25-15.28%
Nov 25-14.91%
Oct 25-15.7%
Oct 25-13.9%
Oct 25-15.45%
Oct 25-17.99%
Oct 25-19.63%
Sep 25-23.27%
Sep 25-25.15%
Sep 25-24.14%
Sep 25-26.26%
Aug 25-25.4%
Aug 25-21.71%
Aug 25-23.34%
Aug 25-31.41%
Aug 25-24.1%
Jul 25-19.04%
Jul 25-20.35%
Jul 25-22.55%
Jul 25-29.54%
Jun 25-33.54%
Jun 25-36.11%
Jun 25-36.39%
Jun 25-33.18%
May 25-43.43%
May 25-47.36%
May 25-53.85%
May 25-51.78%
May 25-57.45%
Apr 25-61.35%
Apr 25-65.81%
Apr 25-61.7%
Apr 25-73.37%
Mar 25-63.5%
Mar 25-47.01%
Mar 25-39.87%
Mar 25-45.28%
Feb 25-44.76%
Feb 25-38.81%
Feb 25-36.97%
Feb 25-39.07%
Jan 25-36.28%
Jan 25-34.56%
Jan 25-36.97%
Jan 25-31.92%
Jan 25-68.31%
Dec 24-72.55%
Dec 24-70.8%
Dec 24-61.81%
Dec 24-50.79%
Nov 24-42.02%
Nov 24-44.76%
Nov 24-48.27%
Nov 24-38.81%
Nov 24-33.2%
Oct 24-32.32%
Oct 24-28.73%
Price to Book
02.557.51012.5med 5.21Dec 24Apr 25Jul 25Oct 25Feb 26May 26Sep 26
SANA Price to Book by year
PeriodPrice to Book
Sep 265.99
Sep 267.36
Aug 267.52
Aug 267.48
Aug 266.79
Aug 268.17
Jul 267.27
Jul 267.38
Jul 267.31
Jul 268.94
Jul 269.31
Jun 267.94
Jun 267.31
Jun 266.22
Jun 266.22
May 267.66
May 267.13
May 267.13
May 265.52
May 265.15
Apr 265.18
Apr 265.54
Apr 264.86
Apr 265.04
Mar 264.36
Mar 264.9
Mar 265.29
Mar 264.96
Feb 265.62
Feb 265.35
Feb 265.13
Feb 265.24
Jan 265.91
Jan 266.44
Jan 266.11
Jan 266.08
Jan 265.59
Dec 255.88
Dec 255.82
Dec 256.86
Dec 256.84
Nov 255.74
Nov 254.39
Nov 255.32
Nov 255.46
Oct 259.63
Oct 2510.87
Oct 259.78
Oct 258.4
Oct 257.7
Sep 256.5
Sep 256.01
Sep 256.26
Sep 255.76
Aug 255.95
Aug 256.96
Aug 256.48
Aug 253.41
Aug 254.44
Jul 255.62
Jul 255.26
Jul 254.75
Jul 253.62
Jun 253.19
Jun 252.97
Jun 252.94
Jun 253.23
May 252.47
May 252.26
May 251.99
May 252.07
May 251.78
Apr 251.67
Apr 251.56
Apr 251.66
Apr 251.4
Mar 251.61
Mar 252.18
Mar 252.36
Mar 252.08
Feb 252.1
Feb 252.42
Feb 252.54
Feb 252.41
Jan 252.59
Jan 252.72
Jan 252.54
Jan 252.95
Jan 251.38
Dec 241.3
Dec 241.33
Dec 241.52
Dec 241.85
Nov 242.24
Nov 242.1
Nov 241.95
Nov 242.42
Nov 242.53
Oct 242.6
Oct 242.92
Sana Biotechnology, Inc.
SANA
Stockpicker

Video analysis: SANA

All videos

No video analysis for this stock yet. Request one from our team.

Your email is used only to follow up on this request. We do not add you to marketing lists. Privacy Policy

News: SANA

Sana Biotechnology, Inc. (SANA) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript

seekingalpha.com · 10 Sep 2026

Sana Biotechnology, Inc. (SANA) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript

Sana Biotechnology, Inc. (SANA) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript

Sana Biotechnology, Inc. (SANA) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript

seekingalpha.com · 10 Sep 2026

Sana Biotechnology, Inc. (SANA) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript

Sana Biotechnology, Inc. (SANA) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript

Did Sana Biotechnology, Inc. Insiders Breach their Fiduciary Duties to Shareholders?

prnewswire.com · 7 Sep 2026

Did Sana Biotechnology, Inc. Insiders Breach their Fiduciary Duties to Shareholders?

Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible for out-of-pocket payment of our legal fees or expenses.

Sana Biotechnology to Present at September 2026 Investor Conferences

globenewswire.com · 1 Sep 2026

Sana Biotechnology to Present at September 2026 Investor Conferences

SEATTLE, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced that it will webcast its presentations at four investor conferences in September. The presentations will feature a business overview and update.

Sana Biotechnology, Inc. (NASDAQ:SANA) Receives $9.50 Consensus PT from Brokerages

defenseworld.net · 30 Jul 2026

Sana Biotechnology, Inc. (NASDAQ:SANA) Receives $9.50 Consensus PT from Brokerages

Sana Biotechnology, Inc. (NASDAQ: SANA - Get Free Report) has been assigned an average rating of "Moderate Buy" from the nine brokerages that are presently covering the firm, Marketbeat Ratings reports. One analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and seven have assigned a buy recommendation to the

Did Sana Biotechnology, Inc. Insiders Breach their Fiduciary Duties to Shareholders?

prnewswire.com · 29 Jul 2026

Did Sana Biotechnology, Inc. Insiders Breach their Fiduciary Duties to Shareholders?

Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible for out-of-pocket payment of our legal fees or expenses.

3 Promising Genomics Stocks to Add to Your Portfolio in 2026

zacks.com · 20 Jul 2026

3 Promising Genomics Stocks to Add to Your Portfolio in 2026

Genomics is reshaping healthcare, and these three stocks - MYGN, SANA and WVE - stand out as rapid advances in personalized medicine and synthetic biology continue to transform the industry.

Sana (SANA) Upgraded to Buy: Here's What You Should Know

zacks.com · 15 Jul 2026

Sana (SANA) Upgraded to Buy: Here's What You Should Know

Sana (SANA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Similar companies

Disclaimer: The historical data presented on this platform is provided by Financial Modeling Prep. Stock Picker is a platform for informational purposes only and does not provide financial advice. Users are encouraged to conduct their own research and consult with a qualified financial advisor before making investment decisions.